Discovery and Validation of Potential Serum Biomarkers for Heart Failure by Untargeted Metabolomics
Cardiovascular Therapeutics · 2024
DOI: 10.1155/2024/7004371 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Cardiovascular Therapeutics, 2024. Verfasst von Guisheng Zhou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Hospital of Nanjing University of Chinese Medicine Jiangsu Province Hospital of Chinese Medicine 210029, Nanjing, China. Hauptthemen laut MEDLINE: Heart Failure, Metabolomics, Biomarkers, Predictive Value of Tests. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese Pharmaceutical Association.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Detection of biomarkers was extremely important for the early diagnosis, prognosis, and therapy optimization of diseases. The purpose of this study was to investigate the differences in serum metabolites between patients with heart failure (HF) and healthy control (HC) and to diagnose HF qualitatively. In this study, serum samples from 83 patients with HF and 35 HCs were used as the research subjects for untargeted metabolomic analysis using ultraperformance liquid chromatography combined with quadrupole‐time of flight mass spectrometry (UPLC‐QTOF/MS) technology. Potential biomarkers were screened and validated using the orthogonal partial least squares discriminant analysis (OPLS‐DA), random forest (RF), binary logistic regression (BLR), and receiver operating characteristic (ROC) analysis. The results indicated that a total of 43 metabolites were considered as differentially expressed metabolites (DEMs). Among these DEMs, glycodeoxycholate was identified as a specific biomarker of HF. A ROC curve analysis for HC versus HF discrimination showed an area under the ROC curve (AUC) of 0.9853 (95% CI: 0.9859–1.0000), a sensitivity of 95%, and a specificity of 100%. Hence, glycodeoxycholate might serve as a potential biomarker for HF. Furthermore, the amino acid metabolism was screened as the most significantly altered pathway in patients with HF. By identifying serum biomarkers and analyzing metabolic pathways, our study provided opportunities to enhance the understanding of the pathogenesis and early diagnosis of HF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Affiliated Hospital of Nanjing University of Chinese Medicine Jiangsu Province Hospital of Chinese Medicine 210029, Nanjing, China.
- Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization and Jiangsu Key Laboratory for High Technology Research of TCM Formulae Nanjing University of Chinese Medicine 210023, Nanjing, Ch…
- College of the First Clinical Medicine Nanjing University of Chinese Medicine 210023, Nanjing, China.
- Pharmaceutical Sciences Research Center Department of Pharmacy Children's Hospital of Nanjing Medical University 210008, Nanjing, China.
ORCID-Profile: Xiaochao Hu, Chunling Liu, Shijia Liu
Förderung
- Chinese Pharmaceutical Association
Zitieren
APA
Zhou, G., Zhang, J., Guo, H., Hu, X., Wang, Y., Shi, K., Liu, T., Yin, S., Liu, H., Liu, C., & Liu, S. (2024). Discovery and Validation of Potential Serum Biomarkers for Heart Failure by Untargeted Metabolomics. Cardiovascular Therapeutics. https://doi.org/10.1155/2024/7004371
Vancouver
Zhou G, Zhang J, Guo H, Hu X, Wang Y, Shi K, et al. Discovery and Validation of Potential Serum Biomarkers for Heart Failure by Untargeted Metabolomics. Cardiovascular Therapeutics. 2024. doi:10.1155/2024/7004371
BibTeX
@article{Zhou2024,
author = {Zhou, Guisheng and Zhang, Junzhi and Guo, Hongli and Hu, Xiaochao and Wang, Yingzhuo and Shi, Kunqun and Liu, Tongtong and Yin, Shengyan and Liu, Huanhuan and Liu, Chunling and Liu, Shijia},
title = {Discovery and Validation of Potential Serum Biomarkers for Heart Failure by Untargeted Metabolomics},
journal = {Cardiovascular Therapeutics},
year = {2024},
doi = {10.1155/2024/7004371}
}
EUVIMED